NASDAQ:NUVA

NuVasive (NUVA) Stock Forecast, Price & News

$39.75

0.00 (0.00%)

(As of 09/11/2023)

Compare

Today's Range: $39.75
▼
$39.75
50-Day Range: $38.12
▼
$43.08
52-Week Range: $35.17
▼
$49.53

Volume: N/A
Average Volume: 1.16 million shs
Market Capitalization: $2.08 billion

P/E Ratio: 79.50
Dividend Yield: N/A
Price Target: $50.75

NuVasive MarketRank™ Forecast

Analyst Rating: Hold
2.18 Rating Score
Upside/Downside: 27.7% Upside
$50.75 Price Target
Short Interest: Healthy
10.98% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.30
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 16.67%
From $2.22 to $2.59 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

431st out of 976 stocks

Medical Devices Industry

6th out of 8 stocks

3.1

Analyst's Opinion

Consensus Rating
NuVasive has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.75, NuVasive has a forecasted upside of 27.7% from its current price of $39.75.
Amount of Analyst Coverage
NuVasive has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
10.98% of the outstanding shares of NuVasive have been sold short.
Short Interest Ratio / Days to Cover
NuVasive has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in NuVasive has recently decreased by 10.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NuVasive does not currently pay a dividend.
Dividend Growth
NuVasive does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVA.

1.3

News and Social Media Coverage

News Sentiment
NuVasive has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NuVasive this week, compared to 4 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NuVasive insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.53% of the stock of NuVasive is held by insiders.

3.1

Earnings and Valuation

Earnings Growth
Earnings for NuVasive are expected to grow by 16.67% in the coming year, from $2.22 to $2.59 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.63.
Price to Earnings Ratio vs. Sector
The P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.14.
Price to Book Value per Share Ratio
NuVasive has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

NUVA Price History

30 days | 90 days | 365 days | Advanced Chart

NUVA Stock News Headlines

September 27, 2023 | finance.yahoo.com

Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023

September 26, 2023 | americanbankingnews.com

NuVasive (NASDAQ:NUVA) Coverage Initiated by Analysts at StockNews.com

September 28, 2023 | UNKNOWN (Ad)

The Bio-Tech Stock That Needs Your Attention!

There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!

September 5, 2023 | finance.yahoo.com

Should You Investigate NuVasive, Inc. (NASDAQ:NUVA) At US$39.75?

September 4, 2023 | msn.com

Globus Medical merges with spine technology company Nuvasive

September 1, 2023 | baystreet.ca

Globus Subsides on Merger with NuVasive

September 1, 2023 | finance.yahoo.com

Globus Medical Completes Merger with NuVasive

August 31, 2023 | finance.yahoo.com

Why NuVasive (NUVA) is a Top Growth Stock for the Long-Term

September 28, 2023 | UNKNOWN (Ad)

The Bio-Tech Stock That Needs Your Attention!

There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!

August 31, 2023 | msn.com

NuVasive/Globus Medical spread widens amid notice of FTC meeting (update)

August 30, 2023 | seekingalpha.com

NuVasive/Globus Medical spread widens amid notice of FTC closed door meeting

August 29, 2023 | marketwatch.com

Goosehead Insurance Shares Rise 17% After Move to SmallCap 600

August 28, 2023 | msn.com

NuVasive gains amid Nasdaq delisting notice for Globus Medical deal

August 18, 2023 | seekingalpha.com

NuVasive: 6.6% Spread With Globus Deal Still Not Enough

August 13, 2023 | theglobeandmail.com

NUVA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NuVasive, Inc. Is Fair to Shareholders

August 7, 2023 | markets.businessinsider.com

Truist Financial Remains a Hold on NuVasive (NUVA)

August 4, 2023 | markets.businessinsider.com

NuVasive Announces Second Quarter 2023 Financial Results

August 3, 2023 | msn.com

NuVasive Non-GAAP EPS of $0.56 beats by $0.01, revenue of $317.8M misses by $5.32M

July 24, 2023 | finance.yahoo.com

NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

July 21, 2023 | morningstar.com

NuVasive Inc NUVA Stock Quote

July 20, 2023 | msn.com

Nuvasive/Globus Medical deal spread widens amid report FTC considering lawsuit

July 19, 2023 | msn.com

Truist Securities Maintains Nuvasive (NUVA) Hold Recommendation

July 18, 2023 | finance.yahoo.com

SMAIO: First-Half 2023 Sales up +203% to €4.0 Million

July 17, 2023 | markets.businessinsider.com

NuVasive (NUVA) Receives a Hold from Truist Financial

July 15, 2023 | markets.businessinsider.com

NuVasive (NUVA) Receives a Buy from RBC Capital

July 6, 2023 | finance.yahoo.com

NUVA - NuVasive, Inc.

June 25, 2023 | latimes.com

Finalist: Gregory Jackson

See More Headlines

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings: 8/02/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Devices
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:NUVA
CUSIP: 67070410
CIK: 1142596
Web: www.nuvasive.com
Phone: (858) 909-1800
Fax: 800-475-9134
Employees: 3,000
Year Founded: 1997

Price Target and Rating

Average Stock Price Forecast: $50.75
High Stock Price Forecast: $58.00
Low Stock Price Forecast: $45.00
Forecasted Upside/Downside: +27.7%
Consensus Rating: Hold
Rating Score (0-4): 2.18
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.50
Trailing P/E Ratio: 79.50
Forward P/E Ratio: 17.91
P/E Growth: N/A
Net Income: $40.41 million
Net Margins: 2.32%
Pretax Margin: 3.41%
Return on Equity: 12.17%
Return on Assets: 4.88%

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 1.25
Quick Ratio: 0.65

Sales & Book Value

Annual Sales: $1.23 billion
Price / Sales: 1.70
Cash Flow: $4.96 per share
Price / Cash Flow: 8.01
Book Value: $17.02 per share
Price / Book: 2.34

Miscellaneous

Outstanding Shares: 52,449,000
Free Float: 52,171,000
Market Cap: $2.08 billion
Optionable: Optionable
Beta: 1.07

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. J. Christopher Barry (Age 50)
CEO & Director
Comp: $3.08M

Mr. Matthew K. Harbaugh (Age 53)
Principal Accounting Officer, CFO & Exec. VP
Comp: $1.37M

Mr. Dale A. Wolf (Age 43)
Sr. VP of Global Operations
Comp: $782.6k

Mr. Nathaniel B. Sisitsky Esq. (Age 48)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $842.84k

Mr. Michael Farrington (Age 39)
Sr. VP of People & Culture
Comp: $626.46k

Mr. Ryan Donahoe
Sr. VP & Chief Technology Officer

Ms. Juliet C. Cunningham
VP of Investor Relations

Mr. Sean Freeman
Sr. VP of Strategy & Corp. Devel.

Ms. Lisa Pecora
VP & Head of Global Commercial Fin.

Ms. Aviva McPherron
Sr. VP of Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View NUVA analyst ratings or view top-rated stocks.
What is NuVasive's stock price forecast for 2023?: 11 analysts have issued 12 month target prices for NuVasive's shares. Their NUVA share price forecasts range from $45.00 to $58.00. On average, they predict the company's stock price to reach $50.75 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.
How have NUVA shares performed in 2023?: NuVasive's stock was trading at $41.24 at the start of the year. Since then, NUVA stock has decreased by 3.6% and is now trading at $39.75.
View the best growth stocks for 2023 here.
When is NuVasive's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NUVA earnings forecast.
How were NuVasive's earnings last quarter?: NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.56. The medical device company had revenue of $317.80 million for the quarter, compared to analysts' expectations of $322.53 million. NuVasive had a net margin of 2.32% and a trailing twelve-month return on equity of 12.17%. The business's revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.47 earnings per share.
What ETFs hold NuVasive's stock?: ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Vanguard S&P Small-Cap 600 Value ETF (VIOV), SPDR S&P 600 Small CapValue ETF (SLYV), iShares S&P Small-Cap 600 Value ETF (IJS) and Syntax Stratified SmallCap ETF (SSLY).
How will NuVasive's stock buyback program work?: NuVasive declared that its Board of Directors has authorized a share repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.
What guidance has NuVasive issued on next quarter's earnings?: NuVasive updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.29 billion.

What is Chris Barry's approval rating as NuVasive's CEO?: 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.
What other stocks do shareholders of NuVasive own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).
What is NuVasive's stock symbol?: NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
Who are NuVasive's major shareholders?: NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include KRYGER CAPITAL Ltd (4.51%), Alpine Associates Management Inc. (3.31%), Dimensional Fund Advisors LP (2.97%), Paradice Investment Management LLC (2.60%), Westchester Capital Management LLC (2.05%) and Geode Capital Management LLC (2.02%). Insiders that own company stock include James Christopher Barry, Lucas Vitale and Massimo Calafiore.
View institutional ownership trends.
How do I buy shares of NuVasive?: Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NuVasive's stock price today?: One share of NUVA stock can currently be purchased for approximately $39.75.
How much money does NuVasive make?: NuVasive (NASDAQ:NUVA) has a market capitalization of $2.08 billion and generates $1.23 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.50 on an earnings per share basis.
How many employees does NuVasive have?: The company employs 3,000 workers across the globe.
Does NuVasive have any subsidiaries?: The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?: NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial